SCHEMBL23064708

SCHEMBL23064708

Cc1ccccc1-n1c(Nc2ccccc2)nc2ccc(Cl)cc2c1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JUN P05412 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
LMNA P02545 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
ALDH1A1 P00352 1/20 0.49
PDE4D Q08499 1/20 0.47
KDM4E B2RXH2 3/20 0.46
HTT P42858 1/20 0.46
TUBB4A P04350 1/20 0.45
TUBB P07437 1/20 0.45
TUBA3C P0DPH7 1/20 0.45
TUBA1B P68363 1/20 0.45
TUBA4A P68366 1/20 0.45
TUBB4B P68371 1/20 0.45
TUBB3 Q13509 1/20 0.45
TUBB2A Q13885 1/20 0.45
TUBB8 Q3ZCM7 1/20 0.45
TUBA3E Q6PEY2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23064709 0.88 KDM4E (0.48) LMNAL3MBTL1KDM4EHTTTUBB4A
SCHEMBL23064706 0.87 TUBB4A (0.46) LMNAL3MBTL1KDM4EHTTTUBB4A
SCHEMBL24089907 0.85 LMNA (0.55) LMNAL3MBTL1ALDH1A1HTTMAPT
SCHEMBL24089978 0.85 TUBB4A (0.48) LMNAL3MBTL1KDM4EHTTTUBB4A
SCHEMBL24090140 0.85 ALDH1A1 (0.68) JUNNFKB1NFKB2RELALMNA
SCHEMBL24090096 0.82 TUBB4A (0.47) LMNAL3MBTL1ALDH1A1KDM4EHTT
SCHEMBL29623326 0.81 TP53 (0.48) JUNNFKB1NFKB2RELALMNA
SCHEMBL24090094 0.81 TP53 (0.48) JUNNFKB1NFKB2RELALMNA
SCHEMBL23065081 0.81 TUBB4A (0.43) LMNAL3MBTL1KDM4EHTTTUBB4A
SCHEMBL23065214 0.81 TUBB4A (0.47) JUNNFKB1NFKB2RELALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed
WO-2021039968-A1 2-AMINOQUINAZOLINONE DERIVATIVE 大日本住友製薬株式会社 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL JUN 2711/4885NFKB1 2159/4885NFKB2 1725/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 JUN 2410/4885NFKB1 2523/4885NFKB2 1785/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 JUN 2410/4885NFKB1 2523/4885NFKB2 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.